Body mass index of 30 kg/m2 or higher is used to identify individuals with obesity. In the last
3 decades, the worldwide prevalence of obesity has increased 27.5% for adults and 47.1 …

Background Globally, diabetic kidney disease (DKD) is the leading cause of end-stage renal
disease. As the most common microvascular complication of diabetes, DKD is a thorny …

Obesity, a primary influence on health condition, causes numerous comorbidities and
complications and, therefore, pharmacotherapy is considered a strategy for its treatment …

There is a new generation of antiobesity drugs in development or just arriving on the scene.
First, setmelanotide has been approved for three of the ultrarare genetic conditions that …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
Western societies and a major cause of hepatic disease worldwide. Its more severe type …

OBJECTIVE To compare the efficacy and safety of liraglutide versus lixisenatide as add-on
to metformin in patients with type 2 diabetes not achieving adequate glycemic control on …

ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …

The ion channel TRPV1 is involved in a wide range of processes including nociception,
thermosensation and, more recently discovered, energy homeostasis. Tightly controlling …

Obesity remains a major public health problem, affecting almost half of adults in the United
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …

The increasing prevalence of nonalcoholic fatty liver disease (NAFLD), which is a
progressive disease, has exerted huge a healthcare burden worldwide. New investigations …